{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:37:50Z","timestamp":1793036270588,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06464-1","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T04:43:34Z","timestamp":1752295414000},"page":"4863-4871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain"],"prefix":"10.1007","volume":"104","author":[{"given":"Carlos","family":"Jim\u00e9nez-Vicente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Beneit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Cano-Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brayan","family":"Merch\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Arnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni Garc\u00eda","family":"Gui\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mart\u00ednez-Bilbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Mart\u00ednez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Alonso-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"L\u00f3pez-Godino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Casta\u00f1o-D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Zugasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"issue":"8","key":"6464_CR1","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.24072","volume":"90","author":"CD DiNardo","year":"2015","unstructured":"DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T et al (2015) Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732\u20136. https:\/\/doi.org\/10.1002\/ajh.24072","journal-title":"Am J Hematol"},{"key":"6464_CR2","doi-asserted-by":"publisher","unstructured":"DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G et al (2023) Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378\u201387. https:\/\/doi.org\/10.1182\/bloodadvances.2022008378","DOI":"10.1182\/bloodadvances.2022008378"},{"issue":"2","key":"6464_CR3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/leu.2010.267","volume":"25","author":"WC Chou","year":"2011","unstructured":"Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL et al (2011) The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 25(2):246\u2013253","journal-title":"Leukemia"},{"issue":"2","key":"6464_CR4","first-page":"326","volume":"1846","author":"RJ Molenaar","year":"2014","unstructured":"Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJF, Bleeker FE (2014) The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochimica et biophysica acta (BBA) -. Reviews Cancer 1846(2):326\u2013341","journal-title":"Reviews Cancer"},{"issue":"6","key":"6464_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK et al (2017) Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130(6):722\u2013731","journal-title":"Blood"},{"issue":"11","key":"6464_CR6","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/s41375-019-0472-2","volume":"33","author":"DA Pollyea","year":"2019","unstructured":"Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS et al (2019) Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia 33(11):2575\u20132584","journal-title":"Leukemia"},{"issue":"7","key":"6464_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","volume":"133","author":"EM Stein","year":"2019","unstructured":"Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK et al (2019) Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 133(7):676\u2013687","journal-title":"Blood"},{"issue":"11","key":"6464_CR8","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","volume":"22","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S et al (2021) Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant- IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol 22(11):1597\u2013608","journal-title":"Lancet Oncol"},{"issue":"11","key":"6464_CR9","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","volume":"7","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G et al (2023) Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378\u20132387","journal-title":"Blood Adv"},{"issue":"1","key":"6464_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","volume":"12","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S et al (2022) Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10. https:\/\/doi.org\/10.1038\/s41408-021-00604-2","journal-title":"Blood Cancer J"},{"issue":"2","key":"6464_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood.2021014901","volume":"141","author":"S de Botton","year":"2023","unstructured":"de Botton S, Montesinos P, Schuh AC, Papayannidis C, Vyas P, Wei AH et al (2023) Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: a randomized phase 3 trial. Blood 141(2):156\u201367. https:\/\/doi.org\/10.1182\/blood.2021014901","journal-title":"Blood"},{"key":"6464_CR12","unstructured":"Arber D, Wang S, Branford S, Foucar K, Gotlib J, Hobbs G et al (2022)\u00a0International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood"},{"key":"6464_CR13","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia"},{"key":"6464_CR14","doi-asserted-by":"publisher","unstructured":"D\u00f6hner H, Wei A, Niederwieser D, R\u00f6llig C Sierra Hospital Santa Creu Sant Pau J, Eytan Stein Memorial Sloan S, Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/doi\/https:\/\/doi.org\/10.1182\/blood.2022016867\/1906555\/blood.2022016867.pdf","DOI":"10.1182\/blood.2022016867\/1906555\/blood.2022016867.pdf"},{"issue":"6","key":"6464_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"6464_CR16","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S et al (2021) Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol 22(11):1597\u2013608. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1470204521004940","DOI":"10.1016\/S1470-2045(21)00494-0"},{"key":"6464_CR17","doi-asserted-by":"publisher","first-page":"106946","DOI":"10.1016\/j.leukres.2022.106946","volume":"122","author":"AJ Klink","year":"2022","unstructured":"Klink AJ, Gajra A, Knoth RL, Marshall L, Hou Y, McBride A, Copher R (2022) Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia. Leuk Res 122:106946. https:\/\/doi.org\/10.1016\/j.leukres.2022.106946","journal-title":"Leuk Res"},{"issue":"2","key":"6464_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ et al (2015) Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 21(2):178\u2013184","journal-title":"Nat Med"},{"issue":"11","key":"6464_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135(11):791\u2013803","journal-title":"Blood"},{"issue":"2","key":"6464_CR20","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1016\/j.clml.2019.11.017","volume":"20","author":"EM Stein","year":"2020","unstructured":"Stein EM, DiNardo CD, Pollyea DA, Schuh AC (2020) Response kinetics and clinical benefits of nonintensive AML therapies in the absence of morphologic response. Clin Lymphoma Myeloma Leuk 20(2):e66\u201375","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"6464_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts. Blood 126(3):291\u2013299","journal-title":"Blood"},{"issue":"21","key":"6464_CR22","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670\u20132677","journal-title":"J Clin Oncol"},{"issue":"12","key":"6464_CR23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1182\/blood.2024024008","volume":"145","author":"GC Issa","year":"2025","unstructured":"Issa GC, Stein EM, DiNardo CD (2025) How I treat: differentiation therapy in acute myeloid leukemia. Blood 145(12):1251\u20131259","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06464-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06464-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06464-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:45Z","timestamp":1761283845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06464-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6464"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06464-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Hospital Cl\u00ednic de Barcelona and conducted following standards set forth by the Declaration of HelsinkiThe study was approved by the Ethics Committee of the Hospital Cl\u00ednic de Barcelona and conducted following standards set forth by the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided their informed consent for the use of laboratory results and genetic analyses.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"CJV serves as educational speaker for AbbVie and Pfizer and received travel grants from AbbVie, Jazz Pharmaceuticals and Pfizer. MDB serves as a consultant for, in an advisory role for, received travel grants from, or served as speaker for BMS, AbbVie, Astellas, JazzPharma, Takeda, and Novartis. JE declares consultancy honoraria from AbbVie, Novartis, Astellas, Jazz Pharmaceuticals, BMS-Celgene, Pfizer, and Daichii-Sankyo, and received research grants from Novartis, Jazz Pharmaceuticals, and Pfizer. The remaining authors declare no competing financial interests. The founders had no role in the design of the study; in the collection, analyses or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}